Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ibuprofen for patent ductus arteriosus closure in term infants
IRCT20190204042618N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ibuprofen in patent ductus arteriosus (PDA) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoint: Closure of patent ductus arteriosus. Started Jul 2018; status: completed.
02
Drugs
ibuprofen
03
Conditions
patent ductus arteriosus (PDA)
Beyond the preview
Go deeper on IRCT20190204042618N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190204042618N1.